Logotype for Oklo Inc

Oklo (OKLO) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oklo Inc

Q4 2024 earnings summary

2 Dec, 2025

Executive summary

  • Achieved major commercial, technological, and regulatory milestones in 2024, including a 12 GW Master Power Agreement with Switch and a 500 MW partnership with Equinix, supported by a $25 million prepayment.

  • Expanded product offering to a scalable 75 MW powerhouse design, targeting high-growth sectors like AI data centers and industrials, with a customer pipeline exceeding 14 GW.

  • Went public on the NYSE under ticker OKLO, strengthening capital position for future growth.

  • Acquired Atomic Alchemy, entering the high-value radioisotope market with potential near-term revenue and less than 1% dilution.

  • Strategic partnerships and acquisitions enhance the technology platform and open new revenue streams.

Financial highlights

  • Full-year operating loss was $52.8 million, including non-cash stock-based compensation and fair value expenses.

  • Adjusted operating loss (excluding non-cash items) was $40.3 million, at the low end of the $40–$50 million forecast.

  • Net loss for 2024 was $73.6 million, including $27.9 million in non-cash fair market value losses on SAFE notes and $0.6 million in tax charges, offset by $7.7 million in interest income.

  • Cash used in operating activities was $38.4 million; year-end cash and marketable securities totaled $275.3 million, driven by $276 million in business combination proceeds.

  • Total assets at year-end were $281.7 million, with stockholders' equity of $250.9 million.

Outlook and guidance

  • 2025 cash used in operations expected to be $65–$80 million, reflecting increased headcount, procurement for the first powerhouse, licensing fees, and Atomic Alchemy integration.

  • Expects to submit the full Combined License Application (COLA) by end of 2024, targeting Q4 to align with ADVANCE Act benefits.

  • Radioisotope revenue from Atomic Alchemy could begin as early as Q1 2026, with licensing milestones for its first radioisotope facility in 2025–2026.

  • Anticipates regulatory fee reductions from the ADVANCE Act to benefit future OpEx.

  • Positioned to accelerate project execution and customer conversions, focusing on AI data center demand and phased multi-reactor deployments.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more